Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Moron, Argentina Clinical Trials

A listing of Moron, Argentina clinical trials actively recruiting patients volunteers.

RESULTS

Found (9) clinical trials

Racotumomab in Patients With High-risk Neuroblastoma

Neuroblastoma is the most common extra-cranial tumor in childhood but prognosis is still poor, even with the advances in its treatment. New therapeutic strategies have been examined, and several immunotherapeutic approaches, including combined therapy with monoclonal antibodies (anti-GD2), intravenous interleukin-2 (Il-2) and intravenous granulocyte-macrophage colony-stimulating factor (GM-CSF), and anti-idiotype vaccines ...

Phase

1.68 miles

Learn More »

Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

This study will determine the dose-response relationship of VAY736 for key efficacy and safety parameters

Phase

2.61 miles

Learn More »

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.

Phase

2.78 miles

Learn More »

A Study to Explore the Antiviral Activity Clinical Outcomes Safety Tolerability and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus

This study will be performed to explore the antiviral activity, clinical outcomes, safety, tolerability, and pharmacokinetics of JNJ-53718678 in adult participants infected with RSV. The study will include both participants who are otherwise healthy (ie, without underlying condition) or who have comorbid conditions (eg, asthma, chronic obstructive pulmonary disease (COPD), ...

Phase

2.88 miles

Learn More »

A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease

The purpose of this study is to evaluate the efficacy of JNJ-active as measured by the change in the Crohn's Disease Activity Index (CDAI) score and Simplified Endoscopic Score for Crohn's disease (SES-CD) from baseline at Week 12.

Phase

4.41 miles

Learn More »

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

A study to evaluate Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 with or without BCG in BCG-Unresponsive non-muscle invasive Bladder Cancer

Phase

5.2 miles

Learn More »

Docetaxel and Ifosfamide in Treating Women With Metastatic Breast Cancer

OBJECTIVES: - Determine the efficacy of docetaxel and ifosfamide as first-line chemotherapy in women with metastatic breast cancer. - Determine the response rate and duration of response of patients treated with this regimen. - Determine the time to treatment failure and survival of patients treated with this regimen. - Determine ...

Phase

6.15 miles

Learn More »

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

JNJ-70033093 is an oral anticoagulant for prevention and treatment of thromboembolic events (for example, VTE) that binds and inhibits activated form of human coagulation Factor XI (FXIa) with high affinity and selectivity. The study will consist of 3 phases: up to 30-day screening phase before total knee replacement (TKR) surgery, ...

Phase

7.15 miles

Learn More »

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

The purpose of this study is to determine whether nivolumab plus ipilimumab or nivolumab alone is effective and safe in the treatment of solid tumors with High Tumor Mutational Burden (TMB-H)

Phase

7.96 miles

Learn More »